Advertisement

Topics

NanOlogy begins NanoPac’s phase 2 study to treat ovarian cancer

03:50 EDT 10 Oct 2017 | Pharmaceutical Business Review
Related Biotechnology, Pharmaceutical and Healthcare News

NanOlogy has commenced the Phase 2 clinical study of intraperitoneally (IP) administered NanoPac (nanoparticle paclitaxel) to treat ovarian cancer.

Original Article: NanOlogy begins NanoPac’s phase 2 study to treat ovarian cancer

NEXT ARTICLE

More From BioPortfolio on "NanOlogy begins NanoPac’s phase 2 study to treat ovarian cancer"

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search
Advertisement
 

Relevant Topic

Ovarian Cancer
Ovarian Cancer is cancer that starts in the female reproductive organs, the ovaries. It is the fifth most common cancer among women.  Women at risk of Ovarian Cancer are those who have had few children (or had children at an older age), carriers o...


News Quicklinks

Search Biotech, Medical and Healthcare News

Popular Biotech, Medical and Healthcare News

Biotech News by Article Type

Biotech News by Location

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches


BioPortfolio Limited Social Media
Publish Content Agreements
Tools Help

HON Code certificate This site complies with the HONcode standard for trustworthy health information:
Verify here.

The information provided by BioPortfolio.com is not a substitute for professional medical advice, diagnosis or treatment. The BioPortfolio site is sponsored BioPortfolio Limited with offices at Stafford House, 10 Prince of Wales Road, Dorchester, DT1 1PW, England. If you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of “Fair Use” and legitimately infringes on your or your client's copyright we may be contacted concerning copyright matters at: priority@bioportfolio.com.
All rights reserved. All other trademarks recognized. Copyright © 1997-2017 BioPortfolio Limited. Site developed by Alacrify Ltd.